MR analysis on the risk of early-onset and advanced prostate cancer identified strong evidence of an association between genetically proxied inhibition of PCSK9 and early-onset disease (OR = 0.70, 95% CI = 0.52 to 0.95, P = 0.023), but weaker evidence of association with advanced prostate cancer (OR = 0.91, 95% CI = 0.74 to 1.12, P = 0.381) (S6 Table). The gene discussed is PCSK9; the disease is prostate cancer.